Zevra Therapeutics
(NASDAQ) ZVRA
Zevra Therapeutics Financials at a Glance
Market Cap
$762.58M
Revenue (TTM)
$122.29M
Net Income (TTM)
$124.22M
EPS (TTM)
$2.15
P/E Ratio
5.99
Dividend
$0.00
Beta (Volatility)
0.93 (Low)
Dividend
$0.00
Beta (Volatility)
0.93 (Low)
Price
$12.92
Volume
44,705
Open
$12.73
Price
$12.92
Volume
44,705
Open
$12.73
Previous Close
$12.92
Daily Range
$12.73 - $13.07
52-Week Range
$7.16 - $14.27
Estimated Earnings Date
Aug 18, 2026
Dividend
$0.00
Beta (Volatility)
0.93 (Low)
Price
$12.92
Volume
44,705
Open
$12.73
Previous Close
$12.92
Daily Range
$12.73 - $13.07
52-Week Range
$7.16 - $14.27
Estimated Earnings Date
Aug 18, 2026
ZVRA News
ZVRA: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Zevra Therapeutics
Industry
Pharmaceuticals
Sector
Health CareEmployees
61
CEO
Neil F. McFarlane
Website
zevra.comHeadquarters
Celebration, FL 34747, US
ZVRA Financials
Key Financial Metrics (TTM)
Gross Margin
86%
Operating Margin
-40%
Net Income Margin
1%
Return on Equity
99%
Return on Capital
-21%
Return on Assets
45%
Earnings Yield
16.69%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$762.58M
Shares Outstanding
59.12M
Volume
44.70K
Avg. Volume
1.44M
Financials (TTM)
Gross Profit
$89.99M
Operating Income
-$4.23M
EBITDA
$98.71M
Operating Cash Flow
-$1.60M
Capital Expenditure
-$835.00K
Free Cash Flow
-$2.43M
Cash & ST Invst.
$191.01M
Total Debt
$63.21M
Zevra Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$36.22M
+77.5%
Gross Profit
$33.96M
+78.2%
Gross Margin
93.75%
N/A
Market Cap
$762.58M
N/A
Market Cap/Employee
$12.93M
N/A
Employees
59
N/A
Net Income
$37.89M
+1322.7%
EBITDA
$43.46M
+2455.0%
Quarterly Fundamentals
Total Cash
$95.60M
+52.6%
Total Debt
$1.15M
-98.1%
Accounts Receivable
$22.10M
+75.1%
Inventory
$2.31M
-9.7%
Long Term Debt
$741.00K
-98.8%
Short Term Debt
$406.00K
-31.1%
Return on Assets
44.59%
N/A
Return on Invested Capital
-21.05%
N/A
Free Cash Flow
$6.11M
+173.4%
Operating Cash Flow
$6.14M
+174.7%